📅 Limited Trading Sessions Ahead
The upcoming Diwali week will be a short one for the Indian stock market, with only three trading sessions scheduled. Markets will remain closed on Tuesday, October 21st, and Wednesday, October 22nd, in observance of the Diwali celebrations.
As we step into this festive yet eventful week, Dalal Street carries a measured sense of optimism, backed by positive cues from the Q2 earnings season and improving foreign institutional inflows (FIIs).
🏦 Market Sentiment: Optimism with a Dash of Caution
The focus remains on Q2 corporate results, with Reliance Industries expected to lead from the front after a stellar quarterly performance. Additionally, investors will closely monitor the results of HDFC Bank, ICICI Bank, UltraTech Cement, and PNB, which were announced over the weekend (Saturday, October 18th).
On the technical front, the Nifty index is likely to defend the support level at 25,300, with resistance seen near the 26,277.35 all-time high and further upside potential toward the psychological 28,000 mark.
Meanwhile, the broader market tone stays constructive, supported by sustained domestic participation and a steady pickup in foreign inflows.
🌏 Global Cues: Trade Optimism from the U.S.
Adding to the optimism, U.S. President Donald Trump stated that the current tariffs on China were “not sustainable” and confirmed plans to meet with President Xi Jinping — a positive signal for global trade sentiment.
📊 Key Earnings on the Radar
Investors can expect an eventful week with several major corporate results lined up:
🔸 Thursday, October 23: HUL, Colgate-Palmolive, Laurus Labs
🔸 Friday, October 24: SBI Life, Dr. Reddy’s Labs, SBI Card, Coforge
🔸 Saturday, October 25: Kotak Mahindra Bank
With global and domestic triggers in play, the market may witness stock-specific movements, presenting opportunities in quality names with strong earnings visibility.
🔍 Nifty & Bank Nifty Forecast
| Index | CMP | Support Levels | Resistance Levels | Trading Range | 200 DMA | PCR | Bias |
|---|---|---|---|---|---|---|---|
| Nifty 50 | 25,710 | 25,300 / 24,851 | 26,000 / 26,500 | 25,511 – 26,000 | 24,301 | 1.06 | Positive |
| Bank Nifty | 57,713 | 56,800 / 55,000 | 59,000 / 60,700 | 56,900 – 58,650 | 53,472 | 1.16 | Positive |
Preferred Trade:
Buy Nifty at CMP (25,710) with targets of 26,000 / 26,277 / 26,500, keeping a stop loss at 25,299.
🔔 Options Data Analysis
The Nifty options setup suggests a trading range between 24,000 and 26,000:
- Maximum Call OI: 26,000, followed by 26,500 (major resistance zone)
- Maximum Put OI: 25,000, followed by 25,500 (support zone)
- Call Writing: Noted at 25,900 and 26,000 strikes
- Put Writing: Active at 25,300 and 25,400 strikes
👉 Interpretation: Nifty remains bullish above 25,300, with momentum confirmation only above 26,277.35.
🚀 Sectoral Outlook
| Bullish Sectors | Bearish Sectors |
|---|---|
| Banking, Auto, FMCG, Defence | IT, Media |
Top Bullish Stocks:
HDFC Bank, BEL, SBI, IDFC First Bank, Bharti Airtel, M&M, HAL, HUL, Trent, TVS Motor, Eicher Motors, Bajaj Finance, Maruti, Britannia
Top Bearish Stocks:
Infosys, PolicyBazaar, Bharat Forge, DMart, KEI, Mphasis, Polycab, OFSS, HDFC AMC, TI India, Dixon, Shree Cement
📈 Stock of the Week: Thyrocare Technologies Ltd. (NSE: THYROCARE)
Recommendation: BUY
CMP: ₹1,244
Target Price: ₹1,701
Stop Loss: ₹977
52-Week High/Low: ₹1,470 / ₹658
Market Cap: ₹6,599 Cr
P/E: 51.7 | EPS (TTM): ₹29.9 | Book Value: ₹101
🧬 Company Overview
Thyrocare Technologies Ltd., founded in 1996 by Dr. A. Velumani, is a leading diagnostics and preventive healthcare company headquartered in Navi Mumbai. The company operates a centralised processing lab in Mumbai and several regional labs across India, offering a wide range of pathology and imaging tests (CLIA, HPLC, LC-MS).
The business model integrates a strong franchise and partner network, supported by hospital and diagnostic tie-ups, now forming part of the PharmEasy / API Holdings group ecosystem.
💪 Key Strengths
- Extensive franchise network of over 9,500 partners ensuring nationwide coverage.
- Strong growth in Tier-2 and Tier-3 cities, with new labs in Bhagalpur, Kashmir, and Roorkee.
- Healthy revenue diversification from both franchise (+20% YoY) and partnership channels (+36% YoY).
⚠️ Risks & Challenges
- Intense competition in a fragmented diagnostics market.
- Dependence on third-party collection centres, exposing the company to operational and compliance risks.
💹 Financial Highlights (Q1 FY26)
| Metric | Q1 FY26 | Q1 FY25 | YoY Growth |
|---|---|---|---|
| Revenue from Operations | ₹193.03 Cr | ₹156.91 Cr | +23% |
| Gross Margin | ₹137.4 Cr (71%) | ₹111.46 Cr (71%) | +23% |
| Profit After Tax (PAT) | ₹38.06 Cr | ₹23.47 Cr | +62% |
| PAT Margin | 20% | 15% | +500 bps |
| Tests Processed | 46.9 Mn | 40.8 Mn | +15% |
| Active Franchisees | 9,500+ | 8,145 | +17% |
📊 Technical & Investment Outlook
Thyrocare is showcasing robust growth momentum with consistent profitability and expanding reach. The stock has seen a steady uptrend since April 2025, with strong support around ₹1,125–1,150.
Preferred Strategy:
Buy at current levels and accumulate on dips.
Targets: ₹1,500 / ₹1,651 / ₹1,750–1,800
Stop Loss: ₹977
Holding Period: 12–15 months
💬 Bottom Line
The only thing that could glitter brighter than Gold and Silver this Diwali might just be the Nifty Index! ✨
Stay cautiously optimistic, focus on earnings-driven quality stocks, and keep a disciplined trading approach as we head into the festive season.
⚠️ Disclaimer
The investments & trading ideas recommended in the market analysis, research reports, etc. may not be suitable for all investors. This article or data points does not construe investment advice as stock market investments are subject to market risks so please refer to your financial consultant advice before Investing or trading. All information is a point of view, and is for educational, Learning and informational use only. The author or the group admin accepts no liability for any interpretation of articles or comments on this platform being used for actual investments. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. Investors must make their own investment decisions based on their specific investment objectives, goals and financial position only after consulting with registered market intermediaries.